India, Aug. 10 -- Shares of Veru Inc. (VERU) are up 17.17% today, following financial results for its fiscal 2026 third quarter ended June 30, 2026, and an update on the progress of its clinical development programs.
The company's lead drug candidate is enobosarm, which is being developed as a potential important combination therapy with GLP-1 receptor agonists for higher quality weight reduction in older patients with obesity.
Business & Clinical Updates:
Veru's Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide for higher-quality weight loss has fully enrolled 239 patients, exceeding its original target of 200 patients.
The company expects the interim analysis and results from the PLATEAU trial in Q1 ...